Back to Stakeholders

Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchSpecialized Academic Departments and Institutes

Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups

Research, Drug Development & ManufacturingAcademic & Non-Profit Research

Research, Drug Development & Manufacturing

New York State Psychiatric Institute

United States

11 Trials

State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.

Academic Research

0 papers

Published Papers

0

Trial Involvement

11

Distinct Focus Topics

0

Latest Publication

Unknown

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

11

Ketamine in the Treatment of Suicidal Depression

Start Date: June 1, 2021
Compounds: Ketamine, Placebo

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Start Date: February 26, 2021
Compounds: Psilocybin

Temporarily not availableIV

IM Ketamine vs Midazolam for Suicidal ER Patients

Start Date: January 2, 2021
Compounds: Ketamine, Placebo

Temporarily not availableI, II

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

Start Date: January 1, 2021
Compounds: Ketamine

Ketamine Treatment Effects on Synaptic Plasticity in Depression

Start Date: October 9, 2020
Compounds: Ketamine

The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use

Start Date: July 1, 2015
Compounds: Ketamine, Placebo

The Effect of Glutamatergic Modulation on Cocaine Self-administration

Start Date: June 1, 2013
Compounds: Ketamine, Placebo

Ketamine for Suicidality in Bipolar Depression

Start Date: January 9, 2013
Compounds: Ketamine, Placebo

NMDA Antagonists in Bipolar Depression

Start Date: January 3, 2013
Compounds: Ketamine

TerminatedI, II

The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Start Date: February 1, 2012
Compounds: Ketamine, Placebo

Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine

Start Date: April 1, 2010
Compounds: Ketamine, Placebo